Introduction
Dendritic cells (DC) are professional antigen-presenting cells of the immune system that initiate the immune response to foreign antigens and may be classified into at least two lineages, myeloid and lymphoid. [1] [2] [3] Myeloid DC (DC1) originate from a bone marrow-derived myeloid precursor forming the majority of DC in peripheral tissues and have immunosurveillant properties. 4 Lymphoid DC (DC2) arise from a lymphoid precursor cell and are thought to play an immunoregulatory role in the immune system. 5 In organ transplantation, myeloid DC of donor origin play a pivotal role in the initiation of the alloimmune response. 6 These myeloid DC reside within the transplanted organ where they are a significant part of the 'passenger leukocyte' population. After transplantation they migrate from the allograft into the lymphoid system of the recipient where, through their ability to directly activate alloantigen-specific recipient T cells, they can initiate allograft rejection via the 'direct' pathway of allorecognition. 7, 8 Three signals are then necessary for DC-induced T cell activation, first, engagement of the T cell receptor with DC major histocompatability molecule-peptide complex (signal 1). Subsequently, T cell activation depends upon the expression of DC co-stimulatory molecules (signal 2) and secretion of the cytokine IL-12 (signal 3). 9, 10 Recently, the cytokines that control DC-induced T cell activation have been identified and it has been recognised that DC can behave in either an immunogenic or tolerogenic manner. 11, 12 DC have the ability to polarize T cells into either aTH1 or TH2 response. The TH1 phenotype is characterized by the expression of interferon gamma and has been associated with allograft rejection. In contrast, the TH2 phenotype is characterized by expression of the cytokines interleukin-4 and -10 and has been associated with allograft acceptance. 13 By using somatic gene therapy techniques with immunosuppressive cytokines it is now possible to genetically engineer DC to favour a tolerogenic response and thus prevent recipient T cell activation. [14] [15] [16] The cytokine IL-10 is an immunosuppressive cytokine with multiple immuno-modulatory effects upon DC function. IL-10 down-regulates cell expression of the DC co-stimulatory molecules CD80 and CD86. 17 IL-10 inhibits DC matu-ration and reduces the capacity of DC to present antigen. IL-10 also inhibits DC production of the potent proinflammatory cytokine IL-12 and therefore skews the T cell response towards TH2. 18 When added to culture medium, IL-10 prevents the final phase of DC maturation.
19,20 Therefore, IL-10 is an attractive cytokine to modify DC function to favour a TH2 response. We used an adenoviral gene delivery strategy to transduce the gene encoding IL-10 into human DC in order to study the in vitro properties of the transduced cells. We then tested the in vivo ability of these genetically modified cells to prevent human skin graft rejection in a small animal transplantation model.
Results
Generation of human myeloid DC Human DC were readily differentiated from monocytes with characteristic clumps of irregularly shaped cells appearing by days 2-3. These cells were typically positive for the cell surface marker CD14 at the commencement of cell culture but lost this marker as culture within the cytokine culture medium progressed. By day 5 greater than 90% of the non-adherent cultured cells had acquired an immature DC phenotype (HLA class I, class II,  CD80   low   , CD86 low , CD83 neg ) ( Figure 1a ) and showed typical appearance when assessed by Giemsa staining of cytocentrifuge preparations (data not shown). These human DC showed potent allostimulatory capacity in two-way mixed leukocyte culture (MLC). This was maximal when DC were matured for 2 days with rhTNF-␣ compared with the immature day 5 human DC (Table 1) .
Transduction of DC with adenoviral gene constructs
Day 5 DC were collected and analysed by flow cytometry to confirm immature DC phenotype (Figure 1a ). In order Gene Therapy to determine the optimal gene transduction conditions, human DC were cultured with the reporter gene adenoviral green fluorescent protein (AdV GFP) at varying multiplicities of infection. We found that by using a ratio of 5000 viral particles to one cell we were consistently able to achieve Ͼ95% transduction efficiency (Figure 2) . In order to assess the effect of adenoviral transduction upon DC viability, trypan blue staining and uptake of EMA on flow cytometry was performed and revealed only minimal cell toxicity (data not shown).
Human DC transduced with an adenoviral interleukin-10 construct inhibit the MLC Using the conditions determined by AdV GFP construct, immature human DC were transduced with an AdV IL-10 gene construct. As a control, day 5 immature DC were also transduced with an adenoviral gene construct with no functional gene cassette (AdV MX-17). The cells were subsequently cultured for up to 48 h in complete medium supplemented with rhTNF-␣. The control virus was highly effective in inducing maturation of human DC (Figure 1b) high . In contrast, cells transduced with the AdV IL-10 gene construct showed down-regulation of class II molecule expression and reduced expression of co-stimulatory molecules CD80, CD86 and CD83 (Figure 1c) . Analysis of messenger RNA within the transduced human DC demonstrated presence of the AdV IL-10 construct within human DC but not in those transduced with AdV MX-17 or in untransduced human DC (data not shown). When these transduced human DC were placed in two-way MLR they profoundly inhibited the proliferative response compared with the cells transduced with the control virus AdV MX-17 ( Figure 3) . In order to confirm the specificity of this effect secondary MLR was per- Mononuclear cells from two unrelated donors (cells A and B) were mixed and showed proliferation in the MLR (AB cells). Allogeneic DC were grown for 5 days as described using rhIL-4 and rhGM-CSF and were then subsequently cultured with or without rhTNF for 2 days (DC+TNF/DC−TNF), before culture with cells from donor A in MLR. Cultures were pulsed with 1 Ci per well 3 H-thymidine for the final 18 h of incubation and thymidine incorporation was measured using scintillation spectrophotometry. Results expressed as mean counts per minute of triplicate experiments ± standard deviation. formed using original donor DC and third-party DC. T cells derived from experiments with AdV IL-10 showed the capacity to proliferate in response to third-party DC but not to DC derived from the original donor indicating a donor-specific inhibitory response (data not shown).
Human DC transduced with adenoviral interleukin-10 secrete IL-10
The secretion of IL-10 was studied in IL-4/GMCSF generated DC and the cells transduced with adenoviral vectors by immunoprecipitation of 35 S metabolic labelled culture supernatant. Immature myeloid DC were shown to secrete IL-10 into tissue culture supernatant by immunopreciptation whereas DC matured with rhTNF-␣ showed no detectable IL-10 ( Figure 4 ). Human DC transduced with AdV MX-17 showed low levels of IL-10 secretion but AdV IL-10 transduction was associated with significantly greater secretion of IL-10 into tissue culture supernatant. In order to test the biological activity of the secreted AdV IL-10, the supernatant was then added to a standard two-way MLC. The inhibitory effect of the IL-10-conditioned medium was reversed by the addition of a anti-interleukin 10 polyclonal antibody. These two results taken together indicate that AdV IL-10 transduced DC were capable of secreting biologically active IL-10 ( Table 2 ).
The effect of transduction of human DC with an adenoviral IL-10 construct upon interleukin-12 production
In order to study the effect of AdV IL-10 transduction upon the stimulatory capacity of DC in MLC we cultured 
NOD-scid mice engrafted with human skin will accept skin grafts indefinitely (Ͼ100 day survival)
Human split thickness skin grafts were obtained from the Department of Surgery (The Queen Elizabeth Hospital) and engrafted successfully on to NOD-scid mice ( Figure  6a ). Human skin grafts remained pink and viable without evidence of rejection for more than 100 days. Analysis of grafted human skin showed that the dermo-epidermal junction remains intact and epidermal blood vessels are patent (Figure 6b ).
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Injection of allogeneic MNC produces rejection of human skin grafts
In order to induce rejection of human skin grafts, the mice were reconstituted with allogeneic mononuclear cells via intraperitoneal injection. Between 2.5 and 3.0 × 10 8 allogeneic mononuclear cells were injected into each mouse. Evidence of skin graft rejection was detectable at 7 days and 14 days and was maximal at 21 days after injection (see Figure 6c) . Changes of rejection were characterized by destruction of the normal skin architecture and infiltration by mononuclear cells of the dermoepidermal junction (see Figure 6c ). Mice (n = 4) engrafted with human skin and reconstituted with human mononuclear cells from the same skin donor showed no evidence of rejection (data not shown).
Co-injection of DC autologous to the skin graft and allogeneic MNC produces accelerated human skin graft rejection
Seven days before humanization, 30-40 ml of human peripheral blood was drawn from the skin donors, and human DC were grown in vitro using recombinant cytokines IL4/GM-CSF for 5 days and then matured for 2 days using rhTNF-␣. Flow cytometric analysis of injected human DC confirmed a 'mature' phenotype with high expression of MHC class I, class II, CD80, CD86 and the DC marker CD83. Autologous human DC (1 × 10 6 cells in 100 l) were then administered to the mouse via intraperitoneal injection at the time of reconstitution with allogeneic mononuclear cells. In contrast to the animals given allogeneic mononuclear cells alone, enhanced skin graft rejection was evident by 7 days (Figure 6d) , with discoloration of the human skin graft evident. In order to study the site of action of genetically modified DC, we transduced immature myeloid IL-4-GM-CSF generated DC with AdV-␤ galactosidase and injected these labelled DC into NOD-scid mice. We found that ␤ galactosidasepositive cells could be identified within the skin graft within 24-48 h of injection. We were unable to detect labelled cells within either the liver or spleen of mice.
Injection of DC transduced with AdV IL-10 protects human skin grafts from rejection by co-injected allogeneic MNC
We then co-injected human DC that had been modified by transduction with AdV IL-10 (n = 6) or the control virus AdV MX-17 (n = 6). In animals that received DC transduced with AdV MX-17 vigorous skin rejection was detected by day 7 which was associated with destruction of the dermo-epidermal junction and lymphocytic infiltration of the subepidermal region (Figure 7a ). In contrast, animals that received DC transduction with AdV IL-10 showed preservation of the skin architecture, with only minimal skin graft infiltration (Figure 7b) . The difference between the two treatments was enhanced at day 14 with animals treated with AdV IL-10 DC (Figure 7d erated myeloid DC) were administered without adenoviral transduction and produced rejection, quantitatively less than DC transduced with AdV MX-17. In order to clarify the mechanism of protection of skin grafts from rejection, fibroblasts were grown from explanted donor skin. These fibroblasts were then transduced with AdV IL-10 and co-administered via intraperitoneal injection with between 2 and 3 × 10 8 allogeneic MNC. In contrast to the effect of AdV IL-10 transduced DC, no protective effect upon skin allografts was observed.
Discussion
Studies in experimental and human transplantation have demonstrated the importance of donor-derived professional antigen-presenting cells or DC in the initiation of the alloimmune response and allograft rejection or acceptance. 6, 11, 21 An approach to modify donor-derived DC in order to induce an immunological hyporesponsive state in the recipient is attractive as a potential strategy in transplantation as it would theoretically allow a reduction in other immunosuppressive therapy and the possibility of donor-specific tolerance. Using gene therapy technology it is now feasible to genetically modify DC to favour such tolerogenic responses. 22 Strategies for the introduction of genes into DC include adenoviral delivery, 23 retroviral delivery, 24, 25 electroporation and chemical means. Of the current options transduction with replication-deficient adenoviral delivery offers a means for achieving high efficiency gene transfer into DC with the advantage of multiple copies of the gene of interest being inserted as compared with a single copy using the retroviral system. 26 As a consequence it is possible to achieve close to 100% gene transduction using adenoviral gene delivery as compared with 30-40% using the retroviral techniques. Using the reporter AdV GFP we were able to achieve a high level of gene transduction at a multiplicity of infection of 5000:1 without significant cell toxicity (Figure 2) . We then used an adenoviral gene Gene Therapy therapy strategy to introduce the gene for IL-10 into human monocyte-derived DC. We confirmed the results of other groups using adenoviral vectors to get high efficiency gene transfer, without significant cell toxicity. 27 Essential to this effective transduction was the addition of the cationic lipid Lipofectamine, which considerably enhanced the adenoviral gene transduction into human DC.
From previous studies it is clear that the maturational status of DC at the time of transplantation is an important determinant of their allostimulatory behaviour. Murine cardiac allografts transplanted with abundant immature DC show prolonged allograft survival in allogeneic recipients. Maturation of these cells within the recipient was associated with subsequent allograft loss. 28 In the immature state, DC express low levels of CD80 and CD86, co-stimulatory molecules that are essential for the amplification of the immune response to foreign peptides. IL-10 has been shown to block DC maturation in vitro. 3, 12, 19, 20 Accordingly, we chose to transduce immature monocyte-derived DC with IL-10. Presentation of donor allopeptide by MHC molecules to recipient T cells in the absence of the so-called 'second signal' provided by co-stimulatory molecules (CD80/CD86) results in an anergic T cell response to that antigen. 29 Our approach was therefore to investigate strategies that might delay maturation of DC to prolong their immature phenotype. In our baseline studies of IL-10 secretion in myeloid DC we found that IL-4/GM-CSF differentiated DC secreted IL-10. The same population of cells treated with a maturational stimulus (TNF) showed no IL-10 secretion. In our studies we found that transduction with IL-10 was a highly effective strategy for maintaining an immature DC phenotype, in that DC transduced with IL-10 were resistant to the effects of the DC maturational cytokine rhTNF-␣ (Table 2 ). These IL-10 transduced human DC were less stimulatory in the MLC compared with either untransduced immature DC or DC that had been exposed to the control adenoviral gene construct. IL-10 transduced DC showed low cell surface expression of the co-stimulatory molecules CD80 and CD86. Others have observed similar results when exogenous IL-10 was added to day 5 immature human DC cultures. 20 One of the major mechanisms by which IL-10 inhibits DC function is by a reduction in the capacity of DC to produce biologically active IL12p70. 18 In our studies of human DC transduced with AdV IL-10 we were unable to demonstrate messenger RNA for IL-12p40, in contrast to human DC transduced with the control virus MX-17. We confirmed using immunoprecipitation with anti-IL-10 that immature IL-4/GM-CSF generated DC secreted IL-10, but this capacity was lost upon treatment of the same cells with TNF ( Figure  4 ). Supernatant from transduced DC was capable of inhibition of the MLC, indicating that transduced DC were secreting biologically active IL-10. The reversal of this effect by the addition of a polyclonal anti-IL-10 antibody showed that IL-10 specifically was responsible for the inhibition. Murine DC have been genetically modified by others using retroviral gene therapy vectors (vIL-10) and adenoviral vectors (TGF-␤ and CTLA4Ig) and have been shown to be an effective strategy both in vitro and in vivo for induction of alloantigen-specific anergy. [30] [31] [32] Recently, DC have also been modified with Fas ligand and proven capable of prolonging allograft survival in a cardiac transplantation model. 33 It is clear from other studies that the form of IL-10 is important to its biological effect. Mammalian or cellular IL-10 may potentially be immunostimulatory. 34 In view of these potential allostimulatory effects viral IL-10 has been the preferred form of IL-10 used for transplantation studies. The mammalian IL-10 used in these studies is of ovine origin and has a molecular sequence that is similar to both cellular human IL-10 and Epstein-Barr virusinduced viral IL-10 (data not shown). The immunosuppressive effect of this mammalian IL-10 upon human DC in vitro is consistent with the alloinhibitory effect of exogenous cellular IL-10 upon human Langerhans cells as described by others. 35 To test the capacity of these genetically modified human DC to prevent allograft rejection we used a chimeric human skin NOD-scid mouse transplant model. This model is similar to the well-characterized humanized scid mouse transplant models, which have been used to test novel immunosuppressive approaches such as CD2/LFA-3 blockade. [36] [37] [38] In these models human skin is engrafted on to an immunocompromised mouse and then reconstituted with allogeneic human peripheral blood mononuclear cells to induce skin allograft rejection. As murine blood vessels grow into the human skin graft and human vessels grow out of the graft, the skin acquires a dual blood supply. Thus the changes of rejection are histological and do not result in skin graft necrosis. 37 The NOD-scid mouse is a severely immunodeficient mouse bred by cross-mating of scid and NOD mice for 10 generations. These animals lack an effective immune system and are deficient in circulating complement. 39, 40 As a recipient for human skin grafts NODscid mice have several advantages compared with scid mice since they lack NK cell activity and show superior ability to be engrafted by haematopoietic stem cells. 40 We found that NOD-scid mice engrafted with human split thickness skin showed indefinite (Ͼ100 days) allograft survival (Figure 5a, b) .
Rejection of skin grafts in humanized scid mice is thought to be mediated by migration of professional antigen-presenting cells from the skin graft into the recipient mouse lymphoid organs in a manner analagous to rejection of solid organs. 38 Mice reconstituted with allogeneic mononuclear cells show rejection of human skin grafts that is characterized by infiltration of the skin graft with mononuclear cells and destruction of the dermo-epidermal junction (DEJ) with changes maximal at day 21 ( Figure 5c ). These results are consistent with the findings of Murray et al 37 who found maximal graft infiltration and destruction between 16 and 21 days after reconstitution with allogeneic cells. We hypothesized that the addition of larger doses of professional antigenpresenting cells that were autologous to the skin graft donor would enhance human skin rejection. The addition of extra professional antigen-presenting cells (in the form of DC) is a means of enhancing the 'direct pathway' of allorecognition, the main route of immune activation for acute cellular rejection of solid organ transplants. In NOD-scid mice treated with DC autologous to the skin graft, accelerated skin graft rejection was observed with maximal destruction much earlier at day 7 (Figure 6d) . Furthermore, it appears that the effect is particular to professional antigen-presenting cells, as skin grafts treated with monocytes failed to show a significantly enhanced rejection response (data not shown). The effect of DC maturation upon skin graft rejection was also marked, with 'mature' DC producing a greater rejection score than immature myeloid DC (Figure 8) . Treatment of animals with DC that had been transduced with AdV IL-10 was effective at prevention of skin graft rejection, compared with animals that received DC transduced with the control virus AdV MX-17 (Figure 7a-d) . In order to investigate the site of action of transduced DC, we labelled IL-4/GM-CSF generated DC with adenoviral ␤ galactosidase (AdV ␤-gal) and injected labelled DC into the peritoneal cavity of grafted NOD-scid mice. We were able to detect DC staining positive for AdV ␤-gal within the skin graft within 24 h of intraperitoneal injection (data not shown). In order to assess the capacity of DC transduced with AdV IL-10 to migrate to T cell-dependent areas within draining lymph nodes an immunocompetent large animal model was utilized. AdV IL-10 transduced DC were labelled with fluorescent dye and found to migrate to T cell-dependent areas within draining lymph nodes. 51 Our in vitro studies suggest that the mechanism of allograft protection is the inability of autologous IL-10 transduced DC to activate allogeneic T cells, via effects on DC co-stimulation molecules CD80/CD86 and the inability of the AdV IL-10 transduced DC to produce IL-12. Critical to graft destruction is the production of cytotoxic T cells (CTL) which produce tissue injury and allograft destruction. Whilst the ability of IL-10 transduced DC to produce CTL was not assessed in this study, other studies have found that IL-10 is capable of inhibiting DC production of CTL to specific antigens. 41 It is therefore possible that one of the mechanisms of allograft protection seen in these experiments is an IL-10-mediated reduction in the donor-specific CTL response. As DC transduced with AdV IL-10 are capable of secretion of IL-10 ( Table 2 ) it is also possible that this paracrine secretion of IL-10 had an immunosuppressive effect upon Langerhans cells or DC resident within the skin grafts modifying their allostimulatory behaviour. Whilst transduction of DC with AdV IL-10 and secretion of IL-10 is clearly important, antigen presentation in the context of IL-10 is essential. Donor fibroblasts when transduced with AdV IL-10 did not modify skin graft rejection compared with AdV IL-10 transduced DC (Figure 8 ). Optimal inhibitory response was seen when DC were transduced with AdV IL-10.
In conclusion, these studies illustrate the potential of human DC as targets for transplantation gene therapy. Human myeloid DC may be grown in vitro, in large numbers and effectively transduced with adenoviral gene therapy vectors encoding immunosuppressive cytokine genes. The in vitro properties of these transduced cells suggest that genetic engineering of human DC is an effective means of modifying the alloimmune response to favour allograft tolerance. In a short-term humanized chimeric skin transplantation model, DC transduced with AdV IL-10 were capable of inhibiting skin graft rejection. Utilising the ability of DC to migrate to the lymphoid organs within the transplant recipient is an attractive means of delivery of immunosuppressive cytokines to sites of antigen presentation without the systemic effects of conventional immunosuppression. 42 The ability of genetically engineered DC to prolong allograft survival in large animals remains to be determined.
Materials and methods
Medium and cytokines
All cell cultures were performed in RPMI complete medium (ICN Biomedicals, Costa Mesa, CA, USA) supplemented with 10% (v/v) fetal bovine serum (Commonwealth Serum Laboratories, Melbourne, Australia) and 1% glutamine. Recombinant hIL-4 was purchased from Peprotech (Nutley, NJ, USA), rhGM-CSF from Schering -Plough (Kenilworth, NJ, USA), recombinant hTNF-␣ from Genzyme Corporation (Cambridge, MA, USA). A rabbit anti-human IL-10 (No. 80-3717-01) polyclonal antibody was purchased from Genzyme Corporation (Cambridge, MA, USA). Cells were grown under humidified conditions in an atmosphere containing 5% CO 2 at 37°C.
DC isolation and culture
Human myeloid DC were generated using well-established protocols. 43 Human PBMNC were isolated from buffy coats of healthy blood donors (Australian Red Cross Blood Transfusion Service, Adelaide, Australia) by Lymphoprep (Nycomed, Oslo, Norway) gradient density separation. The resultant mononuclear cell layer was washed three times in phosphate-buffered saline and then plated on to 3-cm well plates (Falcon) at a concentration of 5 × 10 6 PBMNCs per ml in complete medium for 2 h at 37°C. After incubation the non-adherent cells were washed off and the adherent monocyte fraction was cultured in 3 ml fresh complete medium, supplemented with the rhIL-4 (400 IU/ml) and rhGM-CSF (800 IU/ml). Cells were grown for 5 days after which they were used for in vitro gene therapy studies. For maturation the cells were exposed to rhTNF-␣ at 10 ng/ml for a further 48 h. 
Flow cytometry
Adenoviral gene constructs
The IL-10 gene construct was prepared by the homologous recombination of ovine IL-10 cDNA 44 into an E1-deleted replication-deficient Ad5 adenovirus using the shuttle vector (pXCX3) and driven by a CMV promoter. The adenoviral construct was purified using caesium chloride gradient purification and viral titres were Gene Therapy determined by cytopathic effect assay (CPE). 45, 46 The adenoviral construct AdV MX-17 was an identical adenoviral construct devoid of any cDNA insert. The adenoviral green fluorescence protein (GFP), AdV GFP vector was generated within the laboratory using the AdEASY system. 47 Mixed leukocyte culture (MLC) Allogeneic lymphocytes (1 × 10 5 ) in 100 l complete medium were cultured with 1 × 10 3 DC in 100 l complete medium for 4 days in 96-well plates (Sarstedt, Adelaide, USA). One Ci (37 mBq) of tritiated thymidine (Amersham Life Sciences, Bucks, UK) was added to each well and subsequently harvested after 18 h with a Tomtek Harvester 96 (Hamden, CT, USA). Tritiated thymidine incorporation was determined using a Wallac Microbeta Counter (Turku, Finland). All experiments were performed in triplicate and results were recorded as counts per minute (c.p.m.).
In some experiments, 100 l of a rabbit polyclonal anti human IL-10 antibody (20 g/ml made up in complete medium) were added at the commencement of the reaction.
Metabolic labelling and immunoprecipitation of IL-10 by 35S methionine
Immature DC were differentiated from monocytes and transduced with adenoviral vectors as described. Transduced cells were then centrifuged for 10 min at 800 g to remove any medium and resuspended in 1 ml of methionine/cysteine-free RPMI. Equal numbers of cells were then recentrifuged and 100 Ci/ml of 35 S was then added and the cells incubated for a further 4 h before immunoprecipation using an anti-human IL-10 polyclonal antibody and Staph. aureus. The immunoprecipitated product was then run on a 15% SDS-PAGE gel.
Polymerase chain reaction for messenger RNA RNA was extracted from DC using the method of Chomczynski and Sacchi 48 and was normalised to 1 g before reverse transcription. Reverse transcription and polymerase chain reaction were performed using the following primers: ␤ actin (as per Ref. 49 ) and interleukin 12p40 (forward, 5ЈTTTGGAGATGCTGGGCAGTACA3Ј, reverse, 5ЈGATGATGTCCCTGATGAAGAAGC3Ј).
Transduction of human DC with adenoviral gene constructs DC were transduced using published protocols. 27 Briefly, PBMNC-derived cultured human DC were collected at day 5, centrifuged at 300 g for 10 min, counted and then resuspended at a concentration of 1 × 10 5 cells/100 l serum-free medium. Subsequently, 5 × 10 8 adenoviral particles (5000 particles per cell) were resuspended in 100 l of serum-free medium and 1.25 g of the cationic lipid Lipofectamine (Gibco BRL) and gently agitated for 15 min before transduction of the DC for 2 h at 37°C. Serumfree conditions were used to minimise nonspecific entry of other serum-derived molecules into the cells in competition with the adenovirus. During the transduction period the cells and the adenovirus were gently mixed by aspiration every 15 min in order to ensure maximal cell exposure to the adenoviral particles. After transduction the cells were resuspended in 3 ml of fresh serum-replete
